Completed
A Randomized, Double-blind, comparative trial to evaluate the efficacy, safety and tolerance of combination antiretroviral regimens for the treatment of HIV-1 infection. (AVANTI-Project 113; Protocol 067C): Trial results
Learn MoreCompleted
An International, Double-blind, Randomized, Phase III Study to Evaluate the Tolerance, Safety and Effectiveness of Nevirapine in Preventing Clinical AIDS Progression Events or Death when Used in Combination with 3TC and Stable (4wks) Background Nucleoside Therapy: Trial results
Learn MoreCompleted
A Randomized, Double-blind, Comparative Trial to Evaluate the Efficacy, Safety and Tolerance of Combination Antiretroviral Regimens for the Treatment of HIV-1 Infection: Trial results
Learn MoreCompleted
A Randomized, Double-blind, Comparative Trial to Evaluate the Efficacy, Safety and Tolerance of Combination Antiretroviral Regimens for Treatment of HIV-1 Infection: AZT/3TC vs AZT/3TC/Loviride in Antiretroviral Naïve Patients: Trial results
Learn MoreCompleted
A Phase I Open-Label Study of the Safety and Potential Efficacy of LiGLA (EF-13) in Advanced HIV Infection
Learn MoreCompleted
A Randomized, Controlled, Double-Blinded Trial to Compare the Efficacy and Safety of 3TC vs 3TC + Loviride vs Placebo in the Treatment of HIV-1-Infected Persons Taking Concurrent AZT Containing Treatment Regimens with CD4s between 25 and 250: Trial results
Learn MoreCompleted
A pilot study to assess the potential role of hydroxyurea as an adjuvant therapy among patients with advanced HIV disease receiving didanosine (ddI) therapy
Learn MoreCompleted
A randomized, placebo-controlled, double-blinded, multinational trial comparing the immunologic and virologic effects of nevirapine, ddI and AZT combinations for the treatment of antiretroviral naive HIV+ patients with 200 to 600 T-cells and no AIDS-defining disease: Trial results
Learn MoreCompleted
Combination Therapy for Advanced HIV Disease: A Community-based Randomized Trial of the Safety and Laboratory Effects of ZDV/ddI vs ZDV/ddC
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
